LBF20407HO04 - Revision history

Editor at 00:00, 17 January 2014

2014-01-17T00:00:00Z

@@ Line 14: / Line 14: @@
 |Symbol=8(S),15(S)-DiHETE
 |Biological Activity=8(S),15(S)-diHETE causes chemotaxis of human eosinophils with an ED _{50} of 1.5  &mu; M but is not chemotactic for neutrophils [[Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893|{{RelationTable/GetFirstAuthor|Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893}}]]. 8(S),15(S)-diHETE exhibits hypoalgesic activity by antagonizing the hyperalgesic activity of 8(R),15(S)-diHETE and LTB 4 when measuring nociceptive activity in the rat hindpaw model of pain [[Reference:Oliw_EH:,Biochim. Biophys. Acta,1984,795,384|{{RelationTable/GetFirstAuthor|Reference:Oliw_EH:,Biochim. Biophys. Acta,1984,795,384}}]].
 }}
 {{Lipid/Footer}}

Editor at 04:30, 14 May 2013

2013-05-14T04:30:31Z

← Older revision		Revision as of 13:30, 14 May 2013
Line 7:		Line 7:
	\|LipidMaps=LMFA03060050		\|LipidMaps=LMFA03060050
	\|SysName=(8S,15S) -Dihydroxy- (cis-5,trans-9,cis-11,trans-13) -eicosatetraenoic acid		\|SysName=(8S,15S) -Dihydroxy- (cis-5,trans-9,cis-11,trans-13) -eicosatetraenoic acid
	\|Common Name=&&(8S,15S) -Dihydroxy- (5Z,9E,11Z,13E) -eicosatetraenoic acid&&		\|Common Name=&&(8S,15S) -Dihydroxy- (5Z,9E,11Z,13E) -eicosatetraenoic acid&&8,15-DiHETE&&
	\|UV Spectra= lambda max: 269 nm epsilon : 40,000		\|UV Spectra= lambda max: 269 nm epsilon : 40,000
	\|Source=8(S),15(S)-DiHETE is formed when15(S)-HETE is subjected to further oxidation by 15-lipoxygenase [[Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893\|{{RelationTable/GetFirstAuthor\|Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893}}]].		\|Source=8(S),15(S)-DiHETE is formed when15(S)-HETE is subjected to further oxidation by 15-lipoxygenase [[Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893\|{{RelationTable/GetFirstAuthor\|Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893}}]].

Editor at 07:34, 21 October 2010

2010-10-21T07:34:44Z

← Older revision		Revision as of 16:34, 21 October 2010
Line 6:		Line 6:
	\|LipidBank=DFA8105		\|LipidBank=DFA8105
	\|LipidMaps=LMFA03060050		\|LipidMaps=LMFA03060050
	\|SysName=(8S,15S) -Dihydroxy- (5-cis,9-trans~~,11~~-~~cis,~~13~~-trans~~) -eicosatetraenoic acid		\|SysName=(8S,15S) -Dihydroxy- (cis-5,trans-9,cis-11,trans-13) -eicosatetraenoic acid
	\|Common Name=&&(8S,15S) -Dihydroxy- (5Z,9E,11Z,13E) -eicosatetraenoic acid&&		\|Common Name=&&(8S,15S) -Dihydroxy- (5Z,9E,11Z,13E) -eicosatetraenoic acid&&
	\|UV Spectra= lambda max: 269 nm epsilon : 40,000		\|UV Spectra= lambda max: 269 nm epsilon : 40,000

Editor at 08:02, 2 June 2010

2010-06-02T08:02:19Z

← Older revision		Revision as of 17:02, 2 June 2010
Line 6:		Line 6:
	\|LipidBank=DFA8105		\|LipidBank=DFA8105
	\|LipidMaps=LMFA03060050		\|LipidMaps=LMFA03060050
	\|SysName=(8S,15S) -Dihydroxy- (5-cis,9-trans,11-cis,13-trans) -~~icosatetraenoic~~ acid		\|SysName=(8S,15S) -Dihydroxy- (5-cis,9-trans,11-cis,13-trans) -eicosatetraenoic acid
	\|Common Name=&&(8S,15S) -Dihydroxy- (5Z,9E,11Z,13E) -eicosatetraenoic acid&&		\|Common Name=&&(8S,15S) -Dihydroxy- (5Z,9E,11Z,13E) -eicosatetraenoic acid&&
	\|UV Spectra= lambda max: 269 nm epsilon : 40,000		\|UV Spectra= lambda max: 269 nm epsilon : 40,000

Editor at 02:15, 2 June 2010

2010-06-02T02:15:52Z

← Older revision		Revision as of 11:15, 2 June 2010
Line 7:		Line 7:
	\|LipidMaps=LMFA03060050		\|LipidMaps=LMFA03060050
	\|SysName=(8S,15S) -Dihydroxy- (5-cis,9-trans,11-cis,13-trans) -icosatetraenoic acid		\|SysName=(8S,15S) -Dihydroxy- (5-cis,9-trans,11-cis,13-trans) -icosatetraenoic acid
	\|Common Name=&&(8S,15S) -Dihydroxy- (5Z,9E,11Z,13E) ~~-eicosatetraenoic acid&&8S,15S-dihydroxy-5Z,9E,11Z,13E~~-eicosatetraenoic acid&&		\|Common Name=&&(8S,15S) -Dihydroxy- (5Z,9E,11Z,13E) -eicosatetraenoic acid&&
	\|UV Spectra= lambda max: 269 nm epsilon : 40,000		\|UV Spectra= lambda max: 269 nm epsilon : 40,000
	\|Source=8(S),15(S)-DiHETE is formed when15(S)-HETE is subjected to further oxidation by 15-lipoxygenase [[Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893\|{{RelationTable/GetFirstAuthor\|Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893}}]].		\|Source=8(S),15(S)-DiHETE is formed when15(S)-HETE is subjected to further oxidation by 15-lipoxygenase [[Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893\|{{RelationTable/GetFirstAuthor\|Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893}}]].

Editor at 02:07, 2 June 2010

2010-06-02T02:07:00Z

← Older revision		Revision as of 11:07, 2 June 2010
Line 6:		Line 6:
	\|LipidBank=DFA8105		\|LipidBank=DFA8105
	\|LipidMaps=LMFA03060050		\|LipidMaps=LMFA03060050
	\|SysName=8S,15S-~~dihydroxy~~-5Z,9E,11Z,13E-eicosatetraenoic acid		\|SysName=(8S,15S) -Dihydroxy- (5-cis,9-trans,11-cis,13-trans) -icosatetraenoic acid
	~~\|Common Name=~~&&8S,15S-dihydroxy-5Z,9E,11Z,13E-eicosatetraenoic acid&&		\|Common Name=&&(8S,15S) -Dihydroxy- (5Z,9E,11Z,13E) -eicosatetraenoic acid&&8S,15S-dihydroxy-5Z,9E,11Z,13E-eicosatetraenoic acid&&
	\|UV Spectra= lambda max: 269 nm epsilon : 40,000		\|UV Spectra= lambda max: 269 nm epsilon : 40,000
	\|Source=8(S),15(S)-DiHETE is formed when15(S)-HETE is subjected to further oxidation by 15-lipoxygenase [[Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893\|{{RelationTable/GetFirstAuthor\|Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893}}]].		\|Source=8(S),15(S)-DiHETE is formed when15(S)-HETE is subjected to further oxidation by 15-lipoxygenase [[Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893\|{{RelationTable/GetFirstAuthor\|Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893}}]].

Editor at 09:12, 10 May 2010

2010-05-10T09:12:54Z

← Older revision		Revision as of 18:12, 10 May 2010
Line 13:		Line 13:
	\|Metabolism=		\|Metabolism=
	\|Symbol=8(S),15(S)-DiHETE		\|Symbol=8(S),15(S)-DiHETE
	\|Biological Activity=8(S),15(S)-diHETE causes chemotaxis of human eosinophils with an ED _{50} of 1.5 mu M but is not chemotactic for neutrophils [[Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893\|{{RelationTable/GetFirstAuthor\|Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893}}]]. 8(S),15(S)-diHETE exhibits hypoalgesic activity by antagonizing the hyperalgesic activity of 8(R),15(S)-diHETE and LTB 4 when measuring nociceptive activity in the rat hindpaw model of pain [[Reference:Oliw_EH:,Biochim. Biophys. Acta,1984,795,384\|{{RelationTable/GetFirstAuthor\|Reference:Oliw_EH:,Biochim. Biophys. Acta,1984,795,384}}]].		\|Biological Activity=8(S),15(S)-diHETE causes chemotaxis of human eosinophils with an ED _{50} of 1.5 μ M but is not chemotactic for neutrophils [[Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893\|{{RelationTable/GetFirstAuthor\|Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893}}]]. 8(S),15(S)-diHETE exhibits hypoalgesic activity by antagonizing the hyperalgesic activity of 8(R),15(S)-diHETE and LTB 4 when measuring nociceptive activity in the rat hindpaw model of pain [[Reference:Oliw_EH:,Biochim. Biophys. Acta,1984,795,384\|{{RelationTable/GetFirstAuthor\|Reference:Oliw_EH:,Biochim. Biophys. Acta,1984,795,384}}]].
	}}		}}

	{{Lipid/Footer}}		{{Lipid/Footer}}

Dbmanager at 21:00, 14 April 2010

2010-04-14T21:00:00Z

← Older revision		Revision as of 06:00, 15 April 2010
(No difference)

Dbmanager at 02:59, 12 March 2010

2010-03-12T02:59:04Z

← Older revision		Revision as of 11:59, 12 March 2010
Line 5:		Line 5:
	{{Metabolite		{{Metabolite
	\|LipidBank=DFA8105		\|LipidBank=DFA8105
	\|LipidMaps=-		\|LipidMaps=LMFA03060050
	\|SysName=8S,15S-dihydroxy-5Z,9E,11Z,13E-eicosatetraenoic acid		\|SysName=8S,15S-dihydroxy-5Z,9E,11Z,13E-eicosatetraenoic acid
	\|Common Name=&&8S,15S-dihydroxy-5Z,9E,11Z,13E-eicosatetraenoic acid&&		\|Common Name=&&8S,15S-dihydroxy-5Z,9E,11Z,13E-eicosatetraenoic acid&&

Editor at 10:00, 25 February 2010

2010-02-25T10:00:10Z

← Older revision		Revision as of 19:00, 25 February 2010
Line 13:		Line 13:
	\|Metabolism=		\|Metabolism=
	\|Symbol=8(S),15(S)-DiHETE		\|Symbol=8(S),15(S)-DiHETE
	\|Biological Activity=8(S),15(S)-diHETE causes chemotaxis of human eosinophils with an ED ~~_5 _0~~ of 1.5 mu M but is not chemotactic for neutrophils [[Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893\|{{RelationTable/GetFirstAuthor\|Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893}}]]. 8(S),15(S)-diHETE exhibits hypoalgesic activity by antagonizing the hyperalgesic activity of 8(R),15(S)-diHETE and LTB 4 when measuring nociceptive activity in the rat hindpaw model of pain [[Reference:Oliw_EH:,Biochim. Biophys. Acta,1984,795,384\|{{RelationTable/GetFirstAuthor\|Reference:Oliw_EH:,Biochim. Biophys. Acta,1984,795,384}}]].		\|Biological Activity=8(S),15(S)-diHETE causes chemotaxis of human eosinophils with an ED _{50} of 1.5 mu M but is not chemotactic for neutrophils [[Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893\|{{RelationTable/GetFirstAuthor\|Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893}}]]. 8(S),15(S)-diHETE exhibits hypoalgesic activity by antagonizing the hyperalgesic activity of 8(R),15(S)-diHETE and LTB 4 when measuring nociceptive activity in the rat hindpaw model of pain [[Reference:Oliw_EH:,Biochim. Biophys. Acta,1984,795,384\|{{RelationTable/GetFirstAuthor\|Reference:Oliw_EH:,Biochim. Biophys. Acta,1984,795,384}}]].
	}}		}}

	{{Lipid/Footer}}		{{Lipid/Footer}}